EICHORCondition: Lung Inflammation · Sponsor: Washington University School of Medicine
Interested? Contact the study team ↓
Sponsor, CRO or site team? See where this study is running → — listed sites, countries and recruiting context. Everything below is written for patients and caregivers.
The primary objective of this study is to assess the lung distribution of the Positron Emission Tomography (PET) imaging radiotracer Cu-DOTA-ECL1i, which binds to the specific population inflammatory cells, in patients with fibrotic lung diseases. This objective includes sub-studies to assess radiotracer distribution in the lung, the reproducibility of PET scans and the relationship of the scan to distribution of inflammatory cells in human lung tissue. The overall goal is to assess the potential of the radiotracer to track inflammatory cells in lung diseases.
This description comes directly from the study's public registry record.
Steven Brody, MD · 314-362-8969 · brodys@wustl.edu
There is no obligation to join — the study team can answer your questions about taking part.
Always discuss trial participation with your own doctor first.
Inclusion Criteria: * Men or women 21 years of age or older who have never smoked or current smokers who smoked at least 10 cigarettes per day (1/2 pack) and have smoked at least 100 cigarettes (5 packs) over the past month. * Screening FEV1 and FVC \> 80% of predicted * Capable of lying still and supine within the PET/CT and PET/MR scanner for \~1 hour and follow instructions for breathing protocol during the CT portion * No illicit drug use or other inhaled drug use (including pharmacologic agents, recreational agents, or illicit drugs) within the past year * No known history of cardiac, pulmonary, hepatic or renal disease or diabetes * No history of claustrophobia or other preventing condition that has previously or would interfere with completion of protocol specified imaging sessions * Able to comprehend and willing to follow instructions for the study procedures as called for by the protocol * BMI ≤ 35 Exclusion Criteria: * Currently enrolled in another study using an investigational drug * Pregnancy (confirmed by urine pregnancy test) * Active symptoms or history of cardiac, pulmonary, hepatic or renal disease or diabetes * Currently taking any prescription medications * Presence of an implanted device that is incompatible with CT or MRI scanning * Creatinine \> 1.30 mg/dL, AST \> 50 Units/L, ALT \> 55 Units/L, or total bilirubin \> 1.2 mg/dL
Reproduced word-for-word from the public registry record — the study team can answer questions about it.
| Washington University School of Medicine | St Louis, Missouri, United States | Recruiting |
This study lists sites in the areas below. Each link shows other recruiting studies near that city, from the public registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03492762